Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Peritoneal Neoplasms 1 Melanoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1

Interventions

pembrolizumab 92 Nivolumab 56 Ipilimumab 55 Cyclophosphamide 52 Vemurafenib 28 fludarabine 27 aldesleukin 25 Interleukin-2 25 fludarabine phosphate 21 trametinib 20 dabrafenib 17 Temozolomide 14 Biopsy 14 Cisplatin 13 spartalizumab 12 atezolizumab 12 Carboplatin 11 cobimetinib 10 Specimen Handling 10 Paclitaxel 10 Introns 10 CTLA-4 Antigen 10 poly ICLC 9 binimetinib 9 Radiotherapy 9 Radiosurgery 9 MART-1 Antigen 9 tremelimumab 8 incomplete Freund's adjuvant 8 Radiation 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Melanoma × soluble LAG-3 protein, human × Clear all

NCT02676869 2019-12-18

TACTI-mel

Immutep Australia Pty. Ltd.

Phase 1 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡